Patients as key partners in rare disease drug development
- PMID: 27444223
- DOI: 10.1038/nrd.2016.133
Patients as key partners in rare disease drug development
Abstract
Rare disease drug development could benefit substantially from increased patient engagement and input to enhance understanding of the key aspects of disease impact, ways to measure these impacts and patients' perspectives on the benefit-risk profile of potential therapies.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical